These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 33523413)

  • 1. Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins.
    Jarvi NL; Balu-Iyer SV
    BioDrugs; 2021 Mar; 35(2):125-146. PubMed ID: 33523413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.
    Hamuro L; Kijanka G; Kinderman F; Kropshofer H; Bu DX; Zepeda M; Jawa V
    J Pharm Sci; 2017 Oct; 106(10):2946-2954. PubMed ID: 28576695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development.
    Davis JD; Bravo Padros M; Conrado DJ; Ganguly S; Guan X; Hassan HE; Hazra A; Irvin SC; Jayachandran P; Kosloski MP; Lin KJ; Mukherjee K; Paccaly A; Papachristos A; Partridge MA; Prabhu S; Visich J; Welf ES; Xu X; Zhao A; Zhu M
    Clin Pharmacol Ther; 2024 Mar; 115(3):422-439. PubMed ID: 38093583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous delivery of monoclonal antibodies: How do we get there?
    Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
    J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective.
    Fathallah AM; Bankert RB; Balu-Iyer SV
    AAPS J; 2013 Oct; 15(4):897-900. PubMed ID: 23856740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access.
    Bittner B; Schmidt J
    BioDrugs; 2024 Jan; 38(1):23-46. PubMed ID: 37831325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing Physicochemical Stability of Monoclonal Antibodies in a Simulated Subcutaneous Environment.
    Jogdeo CM; Bhattacharya DS; Lin V; Kolhe P; Badkar A
    J Pharm Sci; 2024 Jul; 113(7):1854-1864. PubMed ID: 38341129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. rHuPH20-facilitated subcutaneous administration of monoclonal antibodies in cancer therapy.
    Dong W; Chen M; Wang J; Xia L; Wang Q; Nie X; Feng Y; Fang Y
    Immunotherapy; 2021 Jan; 13(1):79-88. PubMed ID: 33198539
    [No Abstract]   [Full Text] [Related]  

  • 9. A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics.
    Jarvi NL; Balu-Iyer SV
    Commun Med (Lond); 2023 Dec; 3(1):174. PubMed ID: 38066254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.
    White B; Leon F; White W; Robbie G
    Clin Ther; 2009 Apr; 31(4):728-40. PubMed ID: 19446146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review.
    Xu Z; Leu JH; Xu Y; Nnane I; Liva SG; Wang-Lin SX; Kudgus-Lokken R; Vermeulen A; Ouellet D
    Clin Pharmacol Ther; 2023 May; 113(5):1011-1029. PubMed ID: 36516352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity to biologics: mechanisms, prediction and reduction.
    Sethu S; Govindappa K; Alhaidari M; Pirmohamed M; Park K; Sathish J
    Arch Immunol Ther Exp (Warsz); 2012 Oct; 60(5):331-44. PubMed ID: 22930363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route.
    Felderman J; Ramaiah L; Vazquez-Abad MD; Messing D; Chen Y
    AAPS J; 2024 May; 26(3):60. PubMed ID: 38730115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Precipitation of Antibody Therapeutics After Subcutaneous Injection on Pharmacokinetics and Immunogenicity.
    Kinderman F; Yerby B; Jawa V; Joubert MK; Joh NH; Malella J; Herskovitz J; Xie J; Ferbas J; McBride HJ
    J Pharm Sci; 2019 Jun; 108(6):1953-1963. PubMed ID: 30684540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
    Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
    Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Delivery of Therapeutic Proteins and Peptides: An Overview of Current Technologies and Recommendations for Bridging from Approved Intravenous or Subcutaneous Administration to Novel Oral Regimens.
    Philippart M; Schmidt J; Bittner B
    Drug Res (Stuttg); 2016 Mar; 66(3):113-20. PubMed ID: 26536331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.
    Salazar-Fontana LI; Desai DD; Khan TA; Pillutla RC; Prior S; Ramakrishnan R; Schneider J; Joseph A
    AAPS J; 2017 Mar; 19(2):377-385. PubMed ID: 28083796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick borne encephalitis (TBE) vaccine.
    Hopf S; Garner-Spitzer E; Hofer M; Kundi M; Wiedermann U
    Vaccine; 2016 Apr; 34(17):2027-34. PubMed ID: 26768126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic characterization, benefits and barriers of subcutaneous administration of monoclonal antibodies in oncology.
    Homšek A; Spasić J; Nikolić N; Stanojković T; Jovanović M; Miljković B; Vučićević KM
    J Oncol Pharm Pract; 2023 Mar; 29(2):431-440. PubMed ID: 36349366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taking immunogenicity assessment of therapeutic proteins to the next level.
    Büttel IC; Chamberlain P; Chowers Y; Ehmann F; Greinacher A; Jefferis R; Kramer D; Kropshofer H; Lloyd P; Lubiniecki A; Krause R; Mire-Sluis A; Platts-Mills T; Ragheb JA; Reipert BM; Schellekens H; Seitz R; Stas P; Subramanyam M; Thorpe R; Trouvin JH; Weise M; Windisch J; Schneider CK
    Biologicals; 2011 Mar; 39(2):100-9. PubMed ID: 21353596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.